Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Internal Medicine (Tokyo, Japan)|July 24, 2002
Acute viral encephalitis: the recent progressHiroshi Shoji, Koichi Azuma, Yasuko Nishimura, et al.Japanese Journal of Clinical Oncology|March 13, 2021
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findingsShuichi Taniguchi, Takahiro Yamauchi, Ilseung Choi, et al.International Journal of Hematology|November 28, 2025
A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLLJun Takizawa, Isao Yoshida, Yoshiaki Ogawa, et al.International Journal of Hematology|November 10, 2025
Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 studyKoji Izutsu, Mitsumasa Watanabe, Tomomi Toubai, et al.Inflammatory Intestinal Diseases|September 18, 2018
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance TherapySatoshi Motoya, Mamoru Watanabe, Kori Wallace, et al.International Journal of Hematology|October 23, 2020
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphomaKoji Izutsu, Kazuhito Yamamoto, Koji Kato, et al.Japanese Journal of Clinical Oncology|April 5, 2023
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in JapanNoboru Asada, Jun Ando, Satoru Takada, et al.Cancer Science|October 5, 2021
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trialYoshitaka Narita, Yoshihiro Muragaki, Naoki Kagawa, et al.International Journal of Clinical Oncology|December 19, 2022
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trialMika Mizuno, Kimihiko Ito, Hidekatsu Nakai, et al.Pageof 1